NCT07044037

Brief Summary

This study looks at patients who were treated for cerebral toxoplasmosis at CHSD between 2004 and 2024. It focuses on analyzing their cerebrospinal fluid (CSF) to better understand the biological signs of the disease. The goal is to see if CSF results can show signs of meningitis, even though it's not commonly reported, and to describe any co-infections, symptoms, brain imaging findings, and patient outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 12, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

June 29, 2025

Completed
Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

June 12, 2025

Last Update Submit

June 23, 2025

Conditions

Toxoplasmosis, CerebralToxoplasmosisMeningitisHIV InfectionsCerebrospinal FluidCentral Nervous System Infections

Outcome Measures

Primary Outcomes (1)

  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    From hospital admission to completion of diagnostic lumbar puncture and initial treatment (typically within the first 7 days of hospitalization).

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population includes adult patients (aged 18 years and older) who were hospitalized at the Centre Hospitalier de Saint-Denis (CHSD) between January 1, 2004, and March 31, 2024, with a principal or significant associated diagnosis of cerebral toxoplasmosis.

You may qualify if:

  • \- Adult patients (age 18 years) hospitalized at CHSD between January 1, 2004 and March 31, 2024 for cerebral toxoplasmosis

You may not qualify if:

  • \- Under 18 years ols

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

France

Saint-Denis, France, France

Location

MeSH Terms

Conditions

Toxoplasmosis, CerebralToxoplasmosisMeningitisHIV InfectionsCentral Nervous System Infections

Condition Hierarchy (Ancestors)

Brain AbscessInfectionsCentral Nervous System Protozoal InfectionsCentral Nervous System Parasitic InfectionsParasitic DiseasesCoccidiosisProtozoan InfectionsAbscessSuppurationBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeuroinflammatory DiseasesBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2025

First Posted

June 29, 2025

Study Start

July 1, 2024

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

June 29, 2025

Record last verified: 2025-06

Locations

FR(1)